Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-05-19
2009-11-10
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C536S024310, C536S024330
Reexamination Certificate
active
07615538
ABSTRACT:
The invention provides a method for therapy of rheumatoid arthritis, which comprises administering double-stranded oligonucleotide comprising the nucleotide sequence of 5′-TGAGTCA-3′ to a patient who suffers rheumatoid arthritis.
REFERENCES:
patent: 2005/0113400 (2005-05-01), Chaki et al.
patent: 0 733 370 (1996-09-01), None
patent: WO91/06570 (1991-05-01), None
patent: 91/11535 (1991-08-01), None
patent: 92/07072 (1992-04-01), None
patent: WO92/07072 (1992-04-01), None
patent: 92/18522 (1992-10-01), None
patent: 93/14768 (1993-08-01), None
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Cho-Chung et al., CRE-decoy oligonucleotide-inhibition of gene expression and tumor growth, 2000, Molecular and Cellular Biochemistry, 212, pp. 29-34.
Yoshida et al., Nucleic Acids Research 21(11):2715-2721 (1993).
Shiozawa et al., J. virol. 148(10):3100-3104 (1992).
Richardson et al., Drugs 50(Suppl. 1):26-36(1995).
Harris, Current Opinion in Rheumatology 6:287-289(1994).
Wilder et al., Clinical Orthopaedics and Related Research 265:36-41(1991).
J. Alam et al., “Distal AP-1 Binding Sites Mediate Basal Level Enhancement and TPA Induction of the Mouse Heme Oxygenase-1 Gene”, The Journal of Biological Chemistry, vol. 267, No. 30, pp. 21894-21900 (1992).
Müller-Ladner et al., Scand. J. Rheumatol. 24 (Suppl 101): 115-119 (1995).
Van Lent et al., Scand. J. Rheumatol. 24 (Suppl 101):83-89 (1995).
Zvaifler, Scand. J. Rheumatol. 24 (Suppl 101):67-75 (1995).
Bielinska, A. et al: “Regulation of gene expression with double-stranded phosphorothioate oligonucleotides” Science, vol. 250, 1990, pp. 997-1000.
Ritchlin, C. T. et al: “Potential mechanisms for coordinate gene activation in the rheumatoid synoviocyte: Implications and hypotheses” Springer Seminars in Immunopathology, vol. 11, 1989, pp. 219-234.
Shiozawa, S. et al: “Contribution of synovial mesenchymal cells to the pathogenesis of rheumatoid arthritis” Seminars in Arthritis and Rheumatism, vol. 21, No. 4, 1992, pp. 267-273.
Kuroki, Y. et al: “The contribution of human c-fos DNA to cultured synovia cells: a transfection study” The Journal of Rheumatology, vol. 20, No. 3, Mar. 1993, pp. 422-428.
Shiozawa, S. et al: “Destructive arthritis without lymphocytic infiltration in H2-c-fos transgenic mice” The Journal of Immunology, vol. 148, No. 10, May 15, 1992, pp. 3100-3104.
Kuroki, Y et al: “Constitutive expression of c-fos gene inhibits type 1 collagen synthesis in transected osteoblasts” Biochemical and Biophysical Research Communications, vol. 182, No. 3, 1992, pp. 1389-1394.
Holt, J.T. et al: “Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation” Proceedings of the National Academy of Sciences USA, vol. 83, 1986, pp. 4797-4798.
Takahashi, H. et al: “Anaylsis of the 5′ -upstream promoter region of human involucrin gene: activation by 12-0-tetradecanoylphorbol-13-acetate” The Journal of Investigative Dermatology, vol. 100, No. 1, Jan. 1993, pp. 10-15.
Angel, P. et al: “Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor” Cell, vol. 49, 1987, pp. 729-739.
Anfossi, G. et al: “An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines” Proceedings of the National Academy of Sciences, USA, vol. 86, May 1989, pp. 3379-3383.
Bowman Amy
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Method for therapy of rheumatoid arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for therapy of rheumatoid arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for therapy of rheumatoid arthritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4119810